Wednesday, November 11, 2020
12:00PM – 1:00 PM ET
This virtual program is at 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain, and 9:00AM Pacific.
- Online Personalized Poster Portal
- Interactive, case-based learning environment
- Whiteboard animations
Jacob Sands, MD (PROGRAM CHAIR)
Physician, Dana-Farber Cancer Institute
Instructor of Medicine
Harvard Medical School
This activity is intended to meet the educational needs of medical oncologists, pathologists, and other academic, federal and community-based healthcare practitioners who care for patients with lung cancer.
On completing the program, attendees should be able to:
- Review the current treatment options for patients with EGFR-mutation positive non-small cell lung cancer and resultant therapy resistance
- Discuss antibody-drug conjugates and their evolving role in patients with EGFR resistant, non-small cell lung cancer (NSCLC)
- Explore the new transmembrane marker, TROP2, its role in tumorigenesis, and potential targeted agents to inhibit its effects in patients with NSCLC
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved and/or interested in the therapeutic management of patients with lung cancer.
1.0 ANCC Contact Hours
CNE ACCREDITATION STATEMENT:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]